The establishes the legally binding quality, safety, and manufacturing standards for oral tablet dosage forms across 39 European countries. Managed by the European Directorate for the Quality of Medicines & HealthCare (EDQM) , this general monograph serves as a regulatory cornerstone for pharmaceutical manufacturers, national control laboratories, and regulatory authorities. It guarantees that all tablets sold or distributed within the signatory states maintain rigorous and consistent chemical, physical, and microbiological properties. 1. Scope and Core Definition
Ph. Eur. 0478 allows a "re-test" for disintegration (repeat on 6 new tablets) if 1-2 of the first 6 fail. USP <701> requires that if 1-2 fail, you test 12 more; if more than 2 fail initially, rejection is immediate. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-
The majority of Monograph 0478 is dedicated to mandatory physical tests. Failure in any of these three categories results in batch rejection. The establishes the legally binding quality, safety, and
This is for informational purposes only. For medical advice or diagnosis, consult a professional. AI responses may include mistakes. Learn more What Is European Pharmacopoeia (Ph. Eur.) - Masuu Global 0478 allows a "re-test" for disintegration (repeat on
Before diving into testing, understanding the legal definition is crucial. According to Monograph 0478, a tablet is defined as:
The monograph mandates essential quality tests to ensure safety, efficacy, and consistent manufacturing.
The monograph categorizes tablets into several distinct types, each with specific functional requirements: The basic compressed core.